Novartis Aktie
99,42
EUR
-1,08
EUR
-1,07
%
93,79
CHF
-0,42
CHF
-0,45
%
Kursziele der Novartis-Aktie in CHF
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Jefferies & Company Inc. | 100,00 CHF | +6,62% | 29.04.2025 | |
| UBS AG | 104,00 CHF | +10,89% | 29.04.2025 | |
| Bernstein Research | 115,00 CHF | +22,61% | 29.04.2025 | |
| Goldman Sachs Group Inc. | 102,00 CHF | +8,75% | 28.04.2025 | |
| Deutsche Bank AG | 115,00 CHF | +22,61% | 07.04.2025 | |
| JP Morgan Chase & Co. | 95,00 CHF | +1,29% | 07.04.2025 | |
| DZ BANK | - | - | 03.02.2025 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 86,00 CHF | -8,31% | 07.01.2025 | |
| Barclays Capital | 85,00 CHF | -9,37% | 21.11.2024 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 6 | 3 | 0 | 137,65 GBP | +27,69% |
| Bayer | 1 | 8 | 0 | 25,03 EUR | +8,03% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 3 | 0 | 9,90 EUR | +32,28% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 5 | 1 | 16,53 GBP | +12,15% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 179,43 EUR | +47,19% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 100,25 CHF | +6,89% |
| Pfizer Inc. | 3 | 3 | 0 | 29,20 USD | +22,74% |
| Roche AG (Genussschein) | 3 | 3 | 3 | 281,00 CHF | +3,50% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 6 | 3 | 0 | 115,12 EUR | +19,48% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |